Drug intelligence / Profile preview

ORM-12471

Development stage: Phase 2
Lead developer: Orion
Modality: Small Molecules
Administration: Oral

Overview

ORM-12471 is a small molecule drug candidate developed as an antagonist of the alpha-2C adrenergic receptor (ADRA2C). Its primary mechanism of action is to block the ADRA2C receptor, which plays a role in vasoconstriction and vascular tone. ORM-12471 has been investigated for the prevention of cold-induced vasospasm, particularly in conditions such as Raynaud's phenomenon. The drug was developed by Orion Corporation[1][4].

Targets

ADRA2C (α2C)

Beyond the preview

Go deeper on ORM-12471.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORM-12471.

Explore the full profile